Please assess the completion status of the following clinical trial:

Trial Title: Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed and dated informed consent, and willing and able to comply with protocol requirement;~2. Male or female subjects with rectal cancer ≥18 and \<70 years of age;~3. High risk MRI-defined operable rectal cancer (with an inferior margin no more than 12 cm above the anal verge as assessed by MRI). Presence of at least 1 of the following on high resolution, thin-slice MRI (3 mm):~   Middle Third Tumors~  * mr T3~     1. Extramural vascular invasion (EMVI) positive~    2. Extramural extension \> 5 mms into perirectal fat~    3. Mesorectal fascia (MRF) threatened or involved\*~  * mr T4\*\*\*~   Distal Third Tumors (≤5 cm from anal verge)~  * mr T3 tumor at or below levators~  * T4 as above N2\*\*~     * tumor or lymph node \< 1 mm from the mesorectal fascia \*\*≥4 lymph nodes in the mesorectum showing morphological signs on MRI indicating metastatic disease. ≥4 nodes, whether enlarged or not, with a rounded, homogeneous appearance is thus not sufficient.~       * T4a: overgrowth to an adjacent organ or structure or T4b: peritoneal involvement.~4. Histologically confirmed adenocarcinoma of the rectum. All other histological types are excluded;~5. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤1;~6. Hematological status: neutrophils (ANC) ≥1.5x109/L; platelets ≥100x109/L; hemoglobin ≥9g/dL;~7. Adequate renal function: serum creatinine level \<1.5 x upper limit of normality (ULN);~8. Adequate liver function: serum bilirubin ≤1.5 x ULN, alkaline phosphatase \<5x ULN, AST/ALT \< 3 x ULN;~9. Proteinuria \<2+ (dipstick urinalysis) or ≤1g/24hour;~10. Regular follow-up feasible;~11. For female patients of childbearing potential, negative serum pregnancy test within 1 week (7 days) prior to starting study treatment;~12. Female patients must commit to using reliable and appropriate methods of contraception until at least three months after the end of study treatment (when applicable). Male patients with a partner of childbearing potential must agree to use contraception in addition to having their partner use another contraceptive method during the trial.~Exclusion Criteria:~1. Prior treatment with aflibercept;~2. History or evidence upon physical examination of metastasis;~3. Uncontrolled hypercalcemia;~4. Pre-existing permanent neuropathy (NCI grade ≥2);~5. Uncontrolled hypertension (defined as systolic blood pressure \>150 mmHg and/or diastolic blood pressure \>100 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy;~6. Concomitant protocol unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy);~7. Treatment with any other investigational medicinal product within 28 days prior to study entry;~8. Other concomitant or previous malignancy, except: i/ adequately treated in-situ carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer in complete remission for \>5 years;~9. Any other serious and uncontrolled non-malignant disease, major surgery or traumatic injury within the last 28 days;~10. Pregnant or breastfeeding women;~11. Patients with known allergy to any excipient to study drugs;~12. History of myocardial infarction and/or stroke within 6 months prior to randomization; Previous history of stable angina, uncontrolled arrhythmia, and acute coronary syndrome even if controlled with medication or with myocardial infarction within the last 12 months.~13. Bowel obstruction.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- mFOLFOX6 + Aflibercept (Type: EXPERIMENTAL): - mFOLFOX-6 scheme: 5-Fluoruracil \[5-FU\], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².~- Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml.~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs.
- mFOLFOX6 (Type: ACTIVE_COMPARATOR): - mFOLFOX-6 scheme: 5-Fluoruracil \[5-FU\], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs.

Based on this trial design, predict the completion outcome and termination type (if applicable).